{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:02:33Z","timestamp":1777899753505,"version":"3.51.4"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-024-10169-5","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T10:58:39Z","timestamp":1735297119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?"],"prefix":"10.1007","volume":"52","author":[{"given":"Viktorija","family":"Sokolova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenz M.","family":"Pammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Kocher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckhard","family":"Klieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arno","family":"Amann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Ormanns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Neureiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Seeber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"10169_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2018.05.009","volume":"55","author":"HZ Chen","year":"2019","unstructured":"Chen HZ, Bonneville R, Roychowdhury S (2019) Implementing precision cancer medicine in the genomic era. Semin Cancer Biol 55:16\u201327. https:\/\/doi.org\/10.1016\/j.semcancer.2018.05.009","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"10169_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","volume":"168","author":"DM Hyman","year":"2017","unstructured":"Hyman DM, Taylor BS, Baselga J (2017) Implementing genome-driven oncology. Cell 168(4):584\u2013599. https:\/\/doi.org\/10.1016\/j.cell.2016.12.015","journal-title":"Cell"},{"key":"10169_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.csbj.2019.03.012","volume":"17","author":"K Zimmer","year":"2019","unstructured":"Zimmer K, Kocher F, Spizzo G, Salem M, Gastl G, Seeber A (2019) Treatment according to molecular profiling in relapsed\/refractory cancer patients: a review focusing on latest profiling studies. Comput Struct Biotechnol J 17:447\u2013453. https:\/\/doi.org\/10.1016\/j.csbj.2019.03.012","journal-title":"Comput Struct Biotechnol J"},{"issue":"85","key":"10169_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13045-014-0085-1","volume":"7","author":"GL Gravina","year":"2014","unstructured":"Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C (2014) Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol 7(85):9. https:\/\/doi.org\/10.1186\/s13045-014-0085-1","journal-title":"J Hematol Oncol"},{"key":"10169_CR5","doi-asserted-by":"publisher","unstructured":"Kosyna FK, Depping R (2018) Controlling the gatekeeper: therapeutic targeting of nuclear transport. Cells 7(11). ARTN 221. https:\/\/doi.org\/10.3390\/cells7110221.","DOI":"10.3390\/cells7110221"},{"issue":"2","key":"10169_CR6","first-page":"137","volume":"3","author":"KT Nguyen","year":"2012","unstructured":"Nguyen KT, Holloway MP, Altura RA (2012) The CRM1 nuclear export protein in normal development and disease. Int J Biochem Mol Biol 3(2):137\u2013151","journal-title":"Int J Biochem Mol Biol"},{"issue":"1","key":"10169_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-023-01649-4","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, Guo L, Chen L, Gong B, Jia D, Sun Q (2023) Nuclear transport proteins: structure, function, and disease relevance. Signal Transduct Target Ther 8(1):425. https:\/\/doi.org\/10.1038\/s41392-023-01649-4","journal-title":"Signal Transduct Target Ther"},{"key":"10169_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2014.04.011","volume":"27","author":"AS Azmi","year":"2014","unstructured":"Azmi AS (2014) The evolving role of nuclear transporters in cancer. Semin Cancer Biol 27:1\u20132. https:\/\/doi.org\/10.1016\/j.semcancer.2014.04.011","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10169_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"6657","key":"10169_CR10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/36894","volume":"390","author":"M Fukuda","year":"1997","unstructured":"Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M et al (1997) CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390(6657):308\u2013311. https:\/\/doi.org\/10.1038\/36894","journal-title":"Nature"},{"key":"10169_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0092-8674(00)80370-0","volume":"90","author":"K Stade","year":"1997","unstructured":"Stade K, Ford CS, Guthrie C, Weis K (1997) Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 90:10","journal-title":"Cell"},{"issue":"3","key":"10169_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3390\/cells4030538","volume":"4","author":"A Dickmanns","year":"2015","unstructured":"Dickmanns A, Monecke T, Ficner R (2015) Structural basis of targeting the exportin CRM1 in cancer. Cells 4(3):538\u2013568. https:\/\/doi.org\/10.3390\/cells4030538","journal-title":"Cells"},{"issue":"3","key":"10169_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi AS, Uddin MH, Mohammad RM (2021) The nuclear export protein XPO1\u2014from biology to targeted therapy. Nat Rev Clin Oncol 18(3):152\u2013169. https:\/\/doi.org\/10.1038\/s41571-020-00442-4","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"10169_CR14","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1134\/S0006297922140140","volume":"87","author":"E Kim","year":"2022","unstructured":"Kim E, Mordovkina DA, Sorokin A (2022) Targeting XPO1-dependent nuclear export in cancer. Biochemistry (Mosc) 87(Suppl 1):S178\u2013S170. https:\/\/doi.org\/10.1134\/S0006297922140140","journal-title":"Biochemistry (Mosc)"},{"issue":"10","key":"10169_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/onco.13859","volume":"26","author":"YL Kasamon","year":"2021","unstructured":"Kasamon YL, Price LSL, Okusanya OO, Richardson NC, Li RJ, Ma L et al (2021) FDA approval summary: selinexor for relapsed or refractory diffuse large B-cell lymphoma. Oncologist 26(10):879\u2013886. https:\/\/doi.org\/10.1002\/onco.13859","journal-title":"Oncologist"},{"issue":"2","key":"10169_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2012.10.036","volume":"144","author":"AS Azmi","year":"2013","unstructured":"Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M et al (2013) Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 144(2):447\u2013456. https:\/\/doi.org\/10.1053\/j.gastro.2012.10.036","journal-title":"Gastroenterology"},{"issue":"47","key":"10169_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18632\/oncotarget.19285","volume":"8","author":"AS Azmi","year":"2017","unstructured":"Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E et al (2017) Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget 8(47):12","journal-title":"Oncotarget"},{"key":"10169_CR18","unstructured":"The human genome browser at UCSC (2002). Genome Res."},{"key":"10169_CR19","doi-asserted-by":"publisher","unstructured":"Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S et al (2016) The GeneCards Suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics 54(1):30-31. https:\/\/doi.org\/10.1002\/cpbi.5.","DOI":"10.1002\/cpbi.5"},{"issue":"D1","key":"10169_CR20","doi-asserted-by":"publisher","first-page":"D988","DOI":"10.1093\/nar\/gkab1049","volume":"50","author":"F Cunningham","year":"2022","unstructured":"Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM et al (2022) Ensembl 2022. Nucleic Acids Res 50(D1):D988\u2013D995. https:\/\/doi.org\/10.1093\/nar\/gkab1049","journal-title":"Nucleic Acids Res"},{"key":"10169_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1126\/science.1173388","volume":"324","author":"T Monecke","year":"2009","unstructured":"Monecke T, G\u00fcttler T, Neumann P, Dickmanns A, G\u00f6rlich D, Ficner R (2009) Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science 324:6","journal-title":"Science"},{"issue":"8","key":"10169_CR22","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.str.2013.06.003","volume":"21","author":"C Dian","year":"2013","unstructured":"Dian C, Bernaudat F, Langer K, Oliva MF, Fornerod M, Schoehn G et al (2013) Structure of a truncation mutant of the nuclear export factor CRM1 provides insights into the auto-inhibitory role of its C-terminal helix. Structure 21(8):1338\u20131349. https:\/\/doi.org\/10.1016\/j.str.2013.06.003","journal-title":"Structure"},{"issue":"5","key":"10169_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nsmb.1586","volume":"16","author":"X Dong","year":"2009","unstructured":"Dong X, Biswas A, Chook YM (2009) Structural basis for assembly and disassembly of the CRM1 nuclear export complex. Nat Struct Mol Biol 16(5):558\u2013560. https:\/\/doi.org\/10.1038\/nsmb.1586","journal-title":"Nat Struct Mol Biol"},{"issue":"7242","key":"10169_CR24","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/nature07975","volume":"458","author":"X Dong","year":"2009","unstructured":"Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, Gu H et al (2009) Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 458(7242):1136\u20131141. https:\/\/doi.org\/10.1038\/nature07975","journal-title":"Nature"},{"issue":"D1","key":"10169_CR25","doi-asserted-by":"publisher","first-page":"D418","DOI":"10.1093\/nar\/gkac993","volume":"51","author":"T Paysan-Lafosse","year":"2023","unstructured":"Paysan-Lafosse T, Blum M, Chuguransky S, Grego T, Pinto BL, Salazar GA et al (2023) InterPro in 2022. Nucleic Acids Res 51(D1):D418\u2013D427. https:\/\/doi.org\/10.1093\/nar\/gkac993","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10169_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-017-0412-4","volume":"10","author":"V Camus","year":"2017","unstructured":"Camus V, Miloudi H, Taly A, Sola B, Jardin F (2017) XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol 10(1):47. https:\/\/doi.org\/10.1186\/s13045-017-0412-4","journal-title":"J Hematol Oncol"},{"issue":"21","key":"10169_CR27","doi-asserted-by":"publisher","first-page":"15534","DOI":"10.1021\/acs.jmedchem.1c01145","volume":"64","author":"S Liu","year":"2021","unstructured":"Liu S, Qiao W, Sun Q, Luo Y (2021) Chromosome region maintenance 1 (XPO1\/CRM1) as an anticancer target and discovery of its inhibitor. J Med Chem 64(21):15534\u201315548. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01145","journal-title":"J Med Chem"},{"issue":"23","key":"10169_CR28","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","volume":"120","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y et al (2012) Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia. Blood 120(23):4621\u20134634. https:\/\/doi.org\/10.1182\/blood-2012-05-429506","journal-title":"Blood"},{"issue":"21","key":"10169_CR29","doi-asserted-by":"publisher","first-page":"9487","DOI":"10.1016\/j.bmc.2008.09.051","volume":"16","author":"T Van Neck","year":"2008","unstructured":"Van Neck T, Pannecouque C, Vanstreels E, Stevens M, Dehaen W, Daelemans D (2008) Inhibition of the CRM1-mediated nucleocytoplasmic transport by -azolylacrylates: structure-activity relationship and mechanism of action. Bioorg Med Chem 16(21):9487\u20139497. https:\/\/doi.org\/10.1016\/j.bmc.2008.09.051","journal-title":"Bioorg Med Chem"},{"key":"10169_CR30","doi-asserted-by":"publisher","unstructured":"Muqbil I, Azmi AS, Mohammad RM (2018) Nuclear export inhibition for pancreatic cancer therapy. Cancers (Basel) 10(5). https:\/\/doi.org\/10.3390\/cancers10050138.","DOI":"10.3390\/cancers10050138"},{"key":"10169_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1126\/science.271.5255.1513","volume":"271","author":"D G\u00f6rlich","year":"1996","unstructured":"G\u00f6rlich D, Mattaj IW (1996) Nucleocytoplasmic transport. Science 271:6","journal-title":"Science"},{"issue":"1","key":"10169_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","volume":"13","author":"NG Azizian","year":"2020","unstructured":"Azizian NG, Li Y (2020) XPO1-dependent nuclear export as a target for cancer therapy. J Hematol Oncol 13(1):61. https:\/\/doi.org\/10.1186\/s13045-020-00903-4","journal-title":"J Hematol Oncol"},{"key":"10169_CR33","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3389\/fmicb.2017.01171","volume":"8","author":"C Mathew","year":"2017","unstructured":"Mathew C, Ghildyal R (2017) CRM1 inhibitors for antiviral therapy. Front Microbiol 8:1171. https:\/\/doi.org\/10.3389\/fmicb.2017.01171","journal-title":"Front Microbiol"},{"issue":"26","key":"10169_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/092986708786242859","volume":"15","author":"JG Turner","year":"2008","unstructured":"Turner JG, Sullivan DM (2008) CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 15(26):8","journal-title":"Curr Med Chem"},{"issue":"4","key":"10169_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.tcb.2007.02.003","volume":"17","author":"S Hutten","year":"2007","unstructured":"Hutten S, Kehlenbach RH (2007) CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 17(4):193\u2013201. https:\/\/doi.org\/10.1016\/j.tcb.2007.02.003","journal-title":"Trends Cell Biol"},{"key":"10169_CR36","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1042\/Bj20150368","volume":"468","author":"M Soniat","year":"2015","unstructured":"Soniat M, Chook YM (2015) Nuclear localization signals for four distinct karyopherin-\u03b2 nuclear import systems. Biochem J 468:353\u2013362. https:\/\/doi.org\/10.1042\/Bj20150368","journal-title":"Biochem J"},{"key":"10169_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pharmthera.2016.03.020","volume":"164","author":"A Mahipal","year":"2016","unstructured":"Mahipal A, Malafa M (2016) Importins and exportins as therapeutic targets in cancer. Pharmacol Ther 164:135\u2013143. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.03.020","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10169_CR38","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1083\/jcb.108.4.1195","volume":"108","author":"Y Adachi","year":"1989","unstructured":"Adachi Y, Yanagida M (1989) Higher order chromosome structure is affected by cold-sensitive mutations in a Schizosaccharomyces pombe gene crm1+ which encodes a 115-kD protein preferentially localized in the nucleus and its periphery. J Cell Biol 108(4):1195\u20131207. https:\/\/doi.org\/10.1083\/jcb.108.4.1195","journal-title":"J Cell Biol"},{"issue":"6","key":"10169_CR39","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/ncb1263","volume":"7","author":"A Arnaoutov","year":"2005","unstructured":"Arnaoutov A, Azuma Y, Ribbeck K, Joseph J, Boyarchuk Y, Karpova T et al (2005) Crm1 is a mitotic effector of Ran-GTP in somatic cells. Nat Cell Biol 7(6):626\u2013632. https:\/\/doi.org\/10.1038\/ncb1263","journal-title":"Nat Cell Biol"},{"issue":"3","key":"10169_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.bbrc.2009.04.154","volume":"384","author":"Q Liu","year":"2009","unstructured":"Liu Q, Jiang Q, Zhang C (2009) A fraction of Crm1 locates at centrosomes by its CRIME domain and regulates the centrosomal localization of pericentrin. Biochem Biophys Res Commun 384(3):383\u2013388. https:\/\/doi.org\/10.1016\/j.bbrc.2009.04.154","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10169_CR41","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1091\/mbc.e07-10-1050","volume":"19","author":"L Torosantucci","year":"2008","unstructured":"Torosantucci L, De Luca M, Guarguaglini G, Lavia P, Degrassi F (2008) Localized RanGTP accumulation promotes microtubule nucleation at kinetochores in somatic mammalian cells. Mol Biol Cell 19(5):1873\u20131882. https:\/\/doi.org\/10.1091\/mbc.e07-10-1050","journal-title":"Mol Biol Cell"},{"issue":"7354","key":"10169_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475(7354):101\u2013105. https:\/\/doi.org\/10.1038\/nature10113","journal-title":"Nature"},{"issue":"1","key":"10169_CR43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/leu.2013.263","volume":"28","author":"S Jeromin","year":"2014","unstructured":"Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V et al (2014) SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 28(1):108\u2013117. https:\/\/doi.org\/10.1038\/leu.2013.263","journal-title":"Leukemia"},{"issue":"5","key":"10169_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/ng.2935","volume":"46","author":"DC Lin","year":"2014","unstructured":"Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X et al (2014) Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 46(5):467\u2013473. https:\/\/doi.org\/10.1038\/ng.2935","journal-title":"Nat Genet"},{"issue":"9","key":"10169_CR45","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","volume":"101","author":"V Camus","year":"2016","unstructured":"Camus V, Stamatoullas A, Mareschal S, Viailly PJ, Sarafan-Vasseur N, Bohers E et al (2016) Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica 101(9):1094\u20131101. https:\/\/doi.org\/10.3324\/haematol.2016.145102","journal-title":"Haematologica"},{"issue":"9","key":"10169_CR46","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/ajh.24451","volume":"91","author":"F Jardin","year":"2016","unstructured":"Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S et al (2016) Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. Am J Hematol 91(9):923\u2013930. https:\/\/doi.org\/10.1002\/ajh.24451","journal-title":"Am J Hematol"},{"issue":"24","key":"10169_CR47","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1007\/s00018-016-2292-0","volume":"73","author":"I Garcia-Santisteban","year":"2016","unstructured":"Garcia-Santisteban I, Arregi I, Alonso-Marino M, Urbaneja MA, Garcia-Vallejo JJ, Banuelos S et al (2016) A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K. Cell Mol Life Sci 73(24):4685\u20134699. https:\/\/doi.org\/10.1007\/s00018-016-2292-0","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"10169_CR48","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1158\/2159-8290.CD-19-0298","volume":"9","author":"J Taylor","year":"2019","unstructured":"Taylor J, Sendino M, Gorelick AN, Pastore A, Chang MT, Penson AV et al (2019) Altered nuclear export signal recognition as a driver of oncogenesis. Cancer Discov 9(10):1452\u20131467. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0298","journal-title":"Cancer Discov"},{"issue":"10","key":"10169_CR49","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1097\/PAI.0000000000000820","volume":"28","author":"DLV Maracaja","year":"2020","unstructured":"Maracaja DLV, Puthenpura V, Pels SG, O\u2019Malley DP, Sklar JL, Finberg KE et al (2020) EBV-positive primary large b-cell lymphoma: the role of immunohistochemistry and XPO1 in the diagnosis of mediastinal lymphomas. Appl Immunohistochem Mol Morphol 28(10):725\u2013730. https:\/\/doi.org\/10.1097\/PAI.0000000000000820","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"3","key":"10169_CR50","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41375-021-01483-z","volume":"36","author":"SK Balasubramanian","year":"2022","unstructured":"Balasubramanian SK, Azmi AS, Maciejewski J (2022) Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms. Leukemia 36(3):601\u2013612. https:\/\/doi.org\/10.1038\/s41375-021-01483-z","journal-title":"Leukemia"},{"issue":"78","key":"10169_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13045-014-0078-0","volume":"7","author":"K Parikh","year":"2014","unstructured":"Parikh K, Cang S, Sekhri A, Liu D (2014) Selective inhibitors of nuclear export (SINE)\u2014a novel class of anti-cancer agents. J Hematol Oncol 7(78):8. https:\/\/doi.org\/10.1186\/s13045-014-0078-0","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10169_CR52","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12032-014-0155-9","volume":"31","author":"X Yang","year":"2014","unstructured":"Yang X, Cheng L, Yao L, Ren H, Zhang S, Min X et al (2014) Involvement of chromosome region maintenance 1 (CRM1) in the formation and progression of esophageal squamous cell carcinoma. Med Oncol 31(9):155. https:\/\/doi.org\/10.1007\/s12032-014-0155-9","journal-title":"Med Oncol"},{"key":"10169_CR53","doi-asserted-by":"publisher","first-page":"136","DOI":"10.7150\/jca.1.136","volume":"1","author":"W Sun","year":"2010","unstructured":"Sun W, Yang J (2010) Functional mechanisms for human tumor suppressors. J Cancer 1:136\u2013140. https:\/\/doi.org\/10.7150\/jca.1.136","journal-title":"J Cancer"},{"key":"10169_CR54","doi-asserted-by":"publisher","unstructured":"Saulino DM, Younes PS, Bailey JM, Younes M (2018) CRM1\/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity. Oncotarget 9(30):21289\u201321295. https:\/\/doi.org\/10.18632\/oncotarget.25088.","DOI":"10.18632\/oncotarget.25088"},{"issue":"1","key":"10169_CR55","doi-asserted-by":"publisher","first-page":"12248","DOI":"10.1038\/s41598-018-30686-1","volume":"8","author":"VV Subhash","year":"2018","unstructured":"Subhash VV, Yeo MS, Wang L, Tan SH, Wong FY, Thuya WL et al (2018) Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Sci Rep 8(1):12248. https:\/\/doi.org\/10.1038\/s41598-018-30686-1","journal-title":"Sci Rep"},{"key":"10169_CR56","doi-asserted-by":"publisher","unstructured":"Aladhraei M, Kassem Al-Thobhani A, Poungvarin N, Suwannalert P (2019) Association of XPO1 overexpression with NF-kappaB and Ki67 in colorectal cancer. Asian Pac J Cancer Prev 20(12):3747\u20133754. https:\/\/doi.org\/10.31557\/APJCP.2019.20.12.3747.","DOI":"10.31557\/APJCP.2019.20.12.3747"},{"issue":"W1","key":"10169_CR57","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"ZF Tang","year":"2017","unstructured":"Tang ZF, Li CW, Kang BX, Gao G, Li C, Zhang ZM (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45(W1):W98\u2013W102. https:\/\/doi.org\/10.1093\/nar\/gkx247","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10169_CR58","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3892\/or.2014.3231","volume":"32","author":"PJ van der Watt","year":"2014","unstructured":"van der Watt PJ, Zemanay W, Govender D, Hendricks DT, Parker MI, Leaner VD (2014) Elevated expression of the nuclear export protein, Crm1 (exportin 1), associates with human oesophageal squamous cell carcinoma. Oncol Rep 32(2):730\u2013738. https:\/\/doi.org\/10.3892\/or.2014.3231","journal-title":"Oncol Rep"},{"issue":"7","key":"10169_CR59","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/leu.2017.100","volume":"31","author":"A Cosson","year":"2017","unstructured":"Cosson A, Chapiro E, Bougacha N, Lambert J, Herbi L, Cung HA et al (2017) Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1. Leukemia 31(7):1625\u20131629. https:\/\/doi.org\/10.1038\/leu.2017.100","journal-title":"Leukemia"},{"issue":"2","key":"10169_CR60","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.molcel.2011.11.022","volume":"45","author":"L Golomb","year":"2012","unstructured":"Golomb L, Bublik DR, Wilder S, Nevo R, Kiss V, Grabusic K et al (2012) Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis. Mol Cell 45(2):222\u2013232. https:\/\/doi.org\/10.1016\/j.molcel.2011.11.022","journal-title":"Mol Cell"},{"key":"10169_CR61","doi-asserted-by":"publisher","unstructured":"Gao J, Azmi AS, Aboukameel A, Kauffman M, Shacham S, Abou-Samra AB et al (2014) Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Oncotarget 5(11):3444\u20133454. https:\/\/doi.org\/10.18632\/oncotarget.1813.","DOI":"10.18632\/oncotarget.1813"},{"issue":"1","key":"10169_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-019-0803-9","volume":"12","author":"Y Liu","year":"2019","unstructured":"Liu Y, Azizian NG, Dou Y, Pham LV, Li Y (2019) Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. J Hematol Oncol 12(1):119. https:\/\/doi.org\/10.1186\/s13045-019-0803-9","journal-title":"J Hematol Oncol"},{"issue":"24","key":"10169_CR63","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","volume":"22","author":"P Ranganathan","year":"2016","unstructured":"Ranganathan P, Kashyap T, Yu X, Meng X, Lai TH, McNeil B et al (2016) XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase iialpha to the nucleus. Clin Cancer Res 22(24):6142\u20136152. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2885","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10169_CR64","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.1016\/S0021-9258(17)37374-X","volume":"269","author":"K Nishi","year":"1994","unstructured":"Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S, Beppu T (1994) Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J Biol Chem 269(9):6320\u20136324","journal-title":"J Biol Chem"},{"issue":"16","key":"10169_CR65","doi-asserted-by":"publisher","first-page":"9112","DOI":"10.1073\/pnas.96.16.9112","volume":"96","author":"N Kudo","year":"1999","unstructured":"Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B et al (1999) Leptomycin B inactivates CRM1\/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci U S A 96(16):9112\u20139117. https:\/\/doi.org\/10.1073\/pnas.96.16.9112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10169_CR66","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/bjc.1996.415","volume":"74","author":"ES Newlands","year":"1996","unstructured":"Newlands ES, Rustin GJ, Brampton MH (1996) Phase I trial of elactocin. Br J Cancer 74(4):648\u2013649. https:\/\/doi.org\/10.1038\/bjc.1996.415","journal-title":"Br J Cancer"},{"issue":"4","key":"10169_CR67","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1073\/pnas.1217203110","volume":"110","author":"Q Sun","year":"2013","unstructured":"Sun Q, Carrasco YP, Hu Y, Guo X, Mirzaei H, Macmillan J et al (2013) Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc Natl Acad Sci U S A 110(4):1303\u20131308. https:\/\/doi.org\/10.1073\/pnas.1217203110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10169_CR68","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","volume":"27","author":"HY Fung","year":"2014","unstructured":"Fung HY, Chook YM (2014) Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol 27:52\u201361. https:\/\/doi.org\/10.1016\/j.semcancer.2014.03.002","journal-title":"Semin Cancer Biol"},{"key":"10169_CR69","doi-asserted-by":"crossref","unstructured":"Chen CI, Gutierrez M, Brown PD, Gabrail N, Baz R, Reece DE et al (2013) Anti tumor activity of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) XPO1\/CRM1 antagonist in patients (pts) with relapsed\/refractory multiple myeloma (MM) Or Waldenstrom's macroglobulinemia (WM). Blood 122(21).","DOI":"10.1182\/blood.V122.21.90.90"},{"issue":"7","key":"10169_CR70","doi-asserted-by":"publisher","first-page":"E509","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP et al (2020) Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 7(7):E509\u2013E522","journal-title":"Lancet Haematol"},{"key":"10169_CR71","unstructured":"Savona M, Garzon R, Brown PD, Yee K, Lancet JE, Gutierrez M et al (2013) Phase I Trial of Selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) in patients (pts) with advanced acute myelogenous leukemia (AML). Blood 122(21)."},{"issue":"6","key":"10169_CR72","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-19-1728","volume":"26","author":"AS Azmi","year":"2020","unstructured":"Azmi AS, Khan HY, Muqbil I, Aboukameel A, Neggers JE, Daelemans D et al (2020) Preclinical assessment with clinical validation of selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma. Clin Cancer Res 26(6):1338\u20131348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1728","journal-title":"Clin Cancer Res"},{"key":"10169_CR73","doi-asserted-by":"publisher","unstructured":"Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L et al (2018) A Phase II Trial of selinexor, an oral selective inhibitor of nuclear export compound, in abiraterone- and\/or enzalutamide-refractory metastatic castration-resistant prostate cancer. Oncologist 23(6):656-+. https:\/\/doi.org\/10.1634\/theoncologist.2017-0624.","DOI":"10.1634\/theoncologist.2017-0624"},{"key":"10169_CR74","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ygyno.2022.11.004","volume":"168","author":"SN Westin","year":"2023","unstructured":"Westin SN, Fu SQ, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B et al (2023) Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol 168:76\u201382. https:\/\/doi.org\/10.1016\/j.ygyno.2022.11.004","journal-title":"Gynecol Oncol"},{"issue":"10262","key":"10169_CR75","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M et al (2020) Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 396(10262):1563\u20131573","journal-title":"Lancet"},{"key":"10169_CR76","doi-asserted-by":"publisher","unstructured":"XPO1 Inhibitor Approved for Multiple Myeloma (2019). Cancer Discovery 9(9):1150\u20131151. https:\/\/doi.org\/10.1158\/2159-8290.Cd-nb2019-085.","DOI":"10.1158\/2159-8290.Cd-nb2019-085"},{"key":"10169_CR77","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2248888","author":"CX Chen","year":"2023","unstructured":"Chen CX, Miao XY, Guo XJ, Xu JF, Liang JZ, Zheng Y et al (2023) Safety of selinexor as the only exportin 1 (XPO1) inhibitor so far: a post-marketing study based on the world Health Organization pharmacovigilance database (Vigibase). Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2023.2248888","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10169_CR78","doi-asserted-by":"publisher","first-page":"12231","DOI":"10.1038\/s41598-024-62852-z","volume":"14","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yang R, Feng H, Du Y, Yang B, Zhang M et al (2024) Adverse events reporting of XPO1 inhibitor\u2014selinexor: a real-word analysis from FAERS database. Sci Rep 14(1):12231. https:\/\/doi.org\/10.1038\/s41598-024-62852-z","journal-title":"Sci Rep"},{"key":"10169_CR79","doi-asserted-by":"publisher","unstructured":"Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D et al (2018) Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 36(9):859-+. https:\/\/doi.org\/10.1200\/Jco.2017.75.5207.","DOI":"10.1200\/Jco.2017.75.5207"},{"issue":"3","key":"10169_CR80","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.trecan.2019.02.003","volume":"5","author":"N Chatterjee","year":"2019","unstructured":"Chatterjee N, Bivona TG (2019) Polytherapy and targeted cancer drug resistance. Trends Cancer 5(3):170\u2013182. https:\/\/doi.org\/10.1016\/j.trecan.2019.02.003","journal-title":"Trends Cancer"},{"issue":"12","key":"10169_CR81","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","volume":"18","author":"MP Dias","year":"2021","unstructured":"Dias MP, Moser SC, Ganesan S, Jonkers J (2021) Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol 18(12):773\u2013791. https:\/\/doi.org\/10.1038\/s41571-021-00532-x","journal-title":"Nat Rev Clin Oncol"},{"issue":"7782","key":"10169_CR82","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM (2019) A view on drug resistance in cancer. Nature 575(7782):299\u2013309. https:\/\/doi.org\/10.1038\/s41586-019-1730-1","journal-title":"Nature"},{"issue":"2","key":"10169_CR83","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.yexcr.2004.01.012","volume":"295","author":"R Engel","year":"2004","unstructured":"Engel R, Valkov NI, Gump JL, Hazlehurst L, Dalton WS, Sullivan DM (2004) The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells. Exp Cell Res 295(2):421\u2013431. https:\/\/doi.org\/10.1016\/j.yexcr.2004.01.012","journal-title":"Exp Cell Res"},{"issue":"8","key":"10169_CR84","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","volume":"83","author":"JG Turner","year":"2012","unstructured":"Turner JG, Dawson J, Sullivan DM (2012) Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83(8):1021\u20131032. https:\/\/doi.org\/10.1016\/j.bcp.2011.12.016","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10169_CR85","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/iub.2773","volume":"76","author":"S Newell","year":"2024","unstructured":"Newell S, van der Watt PJ, Leaner VD (2024) Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy. IUBMB Life 76(1):4\u201325. https:\/\/doi.org\/10.1002\/iub.2773","journal-title":"IUBMB Life"},{"key":"10169_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101448","volume":"22","author":"M Sellin","year":"2022","unstructured":"Sellin M, Berg S, Hagen P, Zhang J (2022) The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma. Transl Oncol 22:101448. https:\/\/doi.org\/10.1016\/j.tranon.2022.101448","journal-title":"Transl Oncol"},{"issue":"7","key":"10169_CR87","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3(7):502\u2013516. https:\/\/doi.org\/10.1038\/nrc1123","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10169_CR88","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-16-1333","volume":"23","author":"Y Chen","year":"2017","unstructured":"Chen Y, Camacho SC, Silvers TR, Razak AR, Gabrail NY, Gerecitano JF et al (2017) Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer. Clin Cancer Res 23(6):1552\u20131563. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1333","journal-title":"Clin Cancer Res"},{"key":"10169_CR89","doi-asserted-by":"publisher","unstructured":"Wang ZB, Pan BL, Yao YX, Qiu JC, Zhang XX, Wu XX et al (2023) XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma. Biomed Pharmacotherapy, 160. ARTN 114402. https:\/\/doi.org\/10.1016\/j.biopha.2023.114402.","DOI":"10.1016\/j.biopha.2023.114402"},{"issue":"13","key":"10169_CR90","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18632\/oncotarget.7667","volume":"7","author":"R Nakayama","year":"2016","unstructured":"Nakayama R, Zhang Y, Czaplinski JT, Anatone AJ, Sicinska ET, Fletcher JA et al (2016) Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget 7(13):12","journal-title":"Oncotarget"},{"issue":"1","key":"10169_CR91","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M et al (2014) CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28(1):155\u2013165. https:\/\/doi.org\/10.1038\/leu.2013.115","journal-title":"Leukemia"},{"issue":"15","key":"10169_CR92","doi-asserted-by":"publisher","first-page":"13119","DOI":"10.18632\/oncotarget.3761","volume":"6","author":"M De Cesare","year":"2015","unstructured":"De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P et al (2015) Anti-tumor activity of selective inhibitors of XPO1\/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget 6(15):13119\u201313132","journal-title":"Oncotarget"},{"key":"10169_CR93","doi-asserted-by":"publisher","unstructured":"Deng MM, Zhang MZ, Xu-Monette ZJY, Pham LV, Tzankov A, Visco C et al (2020). XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. J Hematol Oncol 13(1). ARTN 148. https:\/\/doi.org\/10.1186\/s13045-020-00982-3.","DOI":"10.1186\/s13045-020-00982-3"},{"key":"10169_CR94","doi-asserted-by":"publisher","unstructured":"Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C et al (2017) Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res 19. ARTN 93. https:\/\/doi.org\/10.1186\/s13058-017-0878-6.","DOI":"10.1186\/s13058-017-0878-6"},{"key":"10169_CR95","doi-asserted-by":"publisher","unstructured":"Marijon H, Gery S, Chang H, Landesman Y, Shacham S, Lee DH et al (2021) Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status. Oncotarget 12(18):1749\u20131762. https:\/\/doi.org\/10.18632\/oncotarget.28047.","DOI":"10.18632\/oncotarget.28047"},{"key":"10169_CR96","doi-asserted-by":"publisher","unstructured":"He WX, Wang SM, Yan J, Qu YP, Jin L, Sui F et al (2019) Self-assembly of therapeutic peptide into stimuli-responsive clustered nanohybrids for cancer-targeted therapy. Adv Funct Mater 29(10). ARTN 1807736. https:\/\/doi.org\/10.1002\/adfm.201807736.","DOI":"10.1002\/adfm.201807736"},{"issue":"19","key":"10169_CR97","doi-asserted-by":"publisher","first-page":"8513","DOI":"10.7150\/thno.47243","volume":"10","author":"J Yan","year":"2020","unstructured":"Yan J, Ji FP, Yan SQ, You WM, Ma F, Li FN et al (2020) A general-purpose nanohybrid fabricated by Polymeric Au(I)-peptide precursor to wake the function of peptide therapeutics. Theranostics 10(19):8513\u20138527. https:\/\/doi.org\/10.7150\/thno.47243","journal-title":"Theranostics"},{"issue":"6","key":"10169_CR98","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jpha.2023.04.017","volume":"13","author":"LY Gong","year":"2023","unstructured":"Gong LY, Lu YL, Wang J, Li XY, Zhao J, Chen YT et al (2023) Cocktail hepatocarcinoma therapy by a super-assembled nano-pill targeting XPO1 and ATR synergistically. J Pharmaceut Anal 13(6):603\u2013615. https:\/\/doi.org\/10.1016\/j.jpha.2023.04.017","journal-title":"J Pharmaceut Anal"},{"issue":"1","key":"10169_CR99","doi-asserted-by":"publisher","first-page":"276","DOI":"10.7150\/ijbs.66612","volume":"18","author":"L Ou","year":"2022","unstructured":"Ou L, Wang X, Cheng S, Zhang M, Cui R, Hu C et al (2022) Verdinexor, a selective inhibitor of nuclear exportin 1, inhibits the proliferation and migration of esophageal cancer via XPO1\/c-Myc\/FOSL1 Axis. Int J Biol Sci 18(1):276\u2013291. https:\/\/doi.org\/10.7150\/ijbs.66612","journal-title":"Int J Biol Sci"},{"key":"10169_CR100","doi-asserted-by":"publisher","unstructured":"Thein KZ, Fu S, Janku F, Tsimberidou AM, Piha-Paul SA, Karp DD et al (2022) Selinexor in combination with carboplatin and pemetrexed in patients with advanced or metastatic solid tumors results of an open-label, single-center, multi-arm phase 1b study. J Immunother Precis Oncol 5(1):10\u201312. https:\/\/doi.org\/10.36401\/JIPO-21-20.","DOI":"10.36401\/JIPO-21-20"},{"key":"10169_CR101","doi-asserted-by":"publisher","unstructured":"Sexton R, Mahdi Z, Chaudhury R, Beydoun R, Aboukameel A, Khan HY et al (2019) Targeting nuclear exporter protein XPO1\/CRM1 in gastric cancer. Int J Mol Sci 20(19). https:\/\/doi.org\/10.3390\/ijms20194826.","DOI":"10.3390\/ijms20194826"},{"issue":"12","key":"10169_CR102","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/apm.12604","volume":"124","author":"F Zhou","year":"2016","unstructured":"Zhou F, Chen E, You D, Song Y, Sun Z, Yue L (2016) Both high expression of nucleophosmin\/B23 and CRM1 predicts poorer prognosis in human gastric cancer. APMIS 124(12):1046\u20131053. https:\/\/doi.org\/10.1111\/apm.12604","journal-title":"APMIS"},{"issue":"4","key":"10169_CR103","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s12032-013-0726-1","volume":"30","author":"F Zhou","year":"2013","unstructured":"Zhou F, Qiu W, Yao R, Xiang J, Sun X, Liu S et al (2013) CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas. Med Oncol 30(4):726. https:\/\/doi.org\/10.1007\/s12032-013-0726-1","journal-title":"Med Oncol"},{"issue":"6","key":"10169_CR104","doi-asserted-by":"publisher","first-page":"4630","DOI":"10.3892\/ol.2016.5220","volume":"12","author":"M Shintani","year":"2016","unstructured":"Shintani M, Tashiro A, Sangawa A, Yamao N, Kamoshida S (2016) Expression of chromosomal regional maintenance protein-1 may be associated with subcellular survivin expression in human gastric and colorectal carcinoma. Oncol Lett 12(6):4630\u20134634. https:\/\/doi.org\/10.3892\/ol.2016.5220","journal-title":"Oncol Lett"},{"issue":"3","key":"10169_CR105","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-014-2495-8","volume":"74","author":"Y Zheng","year":"2014","unstructured":"Zheng Y, Gery S, Sun H, Shacham S, Kauffman M, Koeffler HP (2014) KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol 74(3):487\u2013495. https:\/\/doi.org\/10.1007\/s00280-014-2495-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"10169_CR106","doi-asserted-by":"publisher","unstructured":"Chen L, Huang Y, Zhou L, Lian Y, Wang J, Chen D et al (2019) Prognostic roles of the transcriptional expression of exportins in hepatocellular carcinoma. Biosci Rep 39(8). https:\/\/doi.org\/10.1042\/BSR20190827.","DOI":"10.1042\/BSR20190827"},{"issue":"1","key":"10169_CR107","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3892\/etm.2016.3283","volume":"12","author":"QL Xie","year":"2016","unstructured":"Xie QL, Liu Y, Zhu Y (2016) Chromosome region maintenance 1 expression and its association with clinical pathological features in primary carcinoma of the liver. Exp Ther Med 12(1):59\u201368. https:\/\/doi.org\/10.3892\/etm.2016.3283","journal-title":"Exp Ther Med"},{"key":"10169_CR108","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.01.025","author":"H Wang","year":"2024","unstructured":"Wang H, Yuan S, Zheng Q, Zhang S, Zhang Q, Ji S et al (2024) Dual Inhibition of CDK4\/6 and XPO1 induces senescence with acquired vulnerability to CRBN-based PROTAC drugs. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2024.01.025","journal-title":"Gastroenterology"},{"key":"10169_CR109","doi-asserted-by":"publisher","unstructured":"Deutzmann A, Sullivan DK, Dhanasekaran R, Li W, Chen XY, Tong L et al (2024) Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma. Nature Commun 15(1). ARTN 963. https:\/\/doi.org\/10.1038\/s41467-024-45128-y.","DOI":"10.1038\/s41467-024-45128-y"},{"issue":"11","key":"10169_CR110","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.7150\/ijbs.80351","volume":"19","author":"L Zhang","year":"2023","unstructured":"Zhang L, Hong JW, Chen W, Zhang W, Liu X, Lu JH et al (2023) DBF4 dependent kinase inhibition suppresses hepatocellular carcinoma progression and potentiates anti-programmed cell death-1 therapy. Int J Biol Sci 19(11):3412\u20133427. https:\/\/doi.org\/10.7150\/ijbs.80351","journal-title":"Int J Biol Sci"},{"issue":"7","key":"10169_CR111","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s00432-021-03626-2","volume":"147","author":"M von Fallois","year":"2021","unstructured":"von Fallois M, Kosyna FK, Mandl M, Landesman Y, Dunst J, Depping R (2021) Selinexor decreases HIF-1alpha via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity. J Cancer Res Clin Oncol 147(7):2025\u20132033. https:\/\/doi.org\/10.1007\/s00432-021-03626-2","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10169_CR112","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12967-022-03635-w","volume":"20","author":"C Zhao","year":"2022","unstructured":"Zhao C, Yang ZY, Zhang J, Li O, Liu SL, Cai C et al (2022) Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53\/mTOR pathway. J Transl Med 20(1):434. https:\/\/doi.org\/10.1186\/s12967-022-03635-w","journal-title":"J Transl Med"},{"issue":"2","key":"10169_CR113","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3892\/ijmm.2016.2628","volume":"38","author":"J Luo","year":"2016","unstructured":"Luo J, Chen Y, Li Q, Wang B, Zhou Y, Lan H (2016) CRM-1 knockdown inhibits extrahepatic cholangiocarcinoma tumor growth by blocking the nuclear export of p27Kip1. Int J Mol Med 38(2):381\u2013390. https:\/\/doi.org\/10.3892\/ijmm.2016.2628","journal-title":"Int J Mol Med"},{"issue":"5","key":"10169_CR114","doi-asserted-by":"publisher","first-page":"5751","DOI":"10.1002\/cam4.5322","volume":"12","author":"C Zhao","year":"2023","unstructured":"Zhao C, Ma B, Yang ZY, Li O, Liu SL, Pan LJ et al (2023) Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation. Cancer Med 12(5):5751\u20135763. https:\/\/doi.org\/10.1002\/cam4.5322","journal-title":"Cancer Med"},{"key":"10169_CR115","doi-asserted-by":"crossref","unstructured":"Huang W, Yue L, Wang L, Zhou X, Sun Y (2009) Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 32(6).","DOI":"10.25011\/cim.v32i6.10668"},{"issue":"30","key":"10169_CR116","doi-asserted-by":"publisher","first-page":"7","DOI":"10.18632\/oncotarget.25088","volume":"9","author":"DM Saulino","year":"2018","unstructured":"Saulino DM, Younes PS, Bailey JM, Younes M (2018) CRM1\/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity. Oncotarget 9(30):7","journal-title":"Oncotarget"},{"key":"10169_CR117","doi-asserted-by":"publisher","unstructured":"Birnbaum DJ, Finetti P, Birnbaum D, Mamessier E, Bertucci F (2019) XPO1 expression is a poor-prognosis marker in pancreatic adenocarcinoma. J Clin Med 8(5). https:\/\/doi.org\/10.3390\/jcm8050596.","DOI":"10.3390\/jcm8050596"},{"key":"10169_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.554502","volume":"11","author":"JH Zhu","year":"2020","unstructured":"Zhu JH, Yan QL, Wang JW, Chen Y, Ye QH, Wang ZJ et al (2020) The key genes for perineural invasion in pancreatic ductal adenocarcinoma identified with Monte-Carlo feature selection method. Front Genet 11:554502. https:\/\/doi.org\/10.3389\/fgene.2020.554502","journal-title":"Front Genet"},{"issue":"9","key":"10169_CR119","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s11095-008-9581-8","volume":"25","author":"AS Azmi","year":"2008","unstructured":"Azmi AS, Ahmad A, Banerjee S, Rangnekar VM, Mohammad RM, Sarkar FH (2008) Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3\u2019 diindolylmethane (DIM). Pharm Res 25(9):2117\u20132124. https:\/\/doi.org\/10.1007\/s11095-008-9581-8","journal-title":"Pharm Res"},{"issue":"9","key":"10169_CR120","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1158\/1535-7163.MCT-08-0438","volume":"7","author":"AS Azmi","year":"2008","unstructured":"Azmi AS, Wang Z, Burikhanov R, Rangnekar VM, Wang G, Chen J et al (2008) Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol Cancer Ther 7(9):2884\u20132893. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0438","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10169_CR121","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/1535-7163.MCT-15-0104","volume":"14","author":"S Kazim","year":"2015","unstructured":"Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T et al (2015) Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer. Mol Cancer Ther 14(7):1570\u20131581. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0104","journal-title":"Mol Cancer Ther"},{"key":"10169_CR122","doi-asserted-by":"publisher","unstructured":"Uddin MH, Al-Hallak MN, Khan HY, Aboukameel A, Li YW, Bannoura SF et al (2023) Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. Clin Transl Med 13(12). ARTN e1513. https:\/\/doi.org\/10.1002\/ctm2.1513.","DOI":"10.1002\/ctm2.1513"},{"issue":"5","key":"10169_CR123","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2767-9764.crc-21-0176","volume":"2","author":"HY Khan","year":"2022","unstructured":"Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R et al (2022) Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C-mutant cancers. Cancer Res Commun 2(5):342\u2013352. https:\/\/doi.org\/10.1158\/2767-9764.crc-21-0176","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10169_CR124","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1053\/j.gastro.2021.03.022","volume":"161","author":"A Inoue","year":"2021","unstructured":"Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL et al (2021) Sequential administration of XPO1 and ATR inhibitors enhances therapeutic response in TP53-mutated colorectal cancer. Gastroenterology 161(1):196\u2013210. https:\/\/doi.org\/10.1053\/j.gastro.2021.03.022","journal-title":"Gastroenterology"},{"issue":"3","key":"10169_CR125","doi-asserted-by":"publisher","first-page":"437","DOI":"10.21037\/jgo.2019.01.17","volume":"10","author":"M Aladhraei","year":"2019","unstructured":"Aladhraei M, Al-Salami E, Poungvarin N,  P (2019) The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients. J Gastrointest Oncol 10(3):437\u2013444. https:\/\/doi.org\/10.21037\/jgo.2019.01.17.","journal-title":"J Gastrointest Oncol"},{"issue":"7","key":"10169_CR126","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1080\/15384047.2015.1047569","volume":"16","author":"M Niu","year":"2015","unstructured":"Niu M, Chong Y, Han Y, Liu X (2015) Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells. Cancer Biol Ther 16(7):1110\u20131118. https:\/\/doi.org\/10.1080\/15384047.2015.1047569","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"10169_CR127","first-page":"2919","volume":"6","author":"M Shintani","year":"2013","unstructured":"Shintani M, Sangawa A, Yamao N, Kamoshida S (2013) Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma. Int J Clin Pathol 6(12):2919\u20132927","journal-title":"Int J Clin Pathol"},{"issue":"4","key":"10169_CR128","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1158\/1535-7163.MCT-16-0553","volume":"16","author":"T Wu","year":"2017","unstructured":"Wu T, Chen W, Zhong Y, Hou X, Fang S, Liu CY et al (2017) Nuclear export of ubiquitinated proteins determines the sensitivity of colorectal cancer to proteasome inhibitor. Mol Cancer Ther 16(4):717\u2013728. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0553","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10169_CR129","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-15-0978","volume":"22","author":"I Ferreiro-Neira","year":"2016","unstructured":"Ferreiro-Neira I, Torres NE, Liesenfeld LF, Chan CH, Penson T, Landesman Y et al (2016) XPO1 inhibition enhances radiation response in preclinical models of rectal cancer. Clin Cancer Res 22(7):1663\u20131673. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0978","journal-title":"Clin Cancer Res"},{"issue":"34","key":"10169_CR130","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","volume":"34","author":"AR Abdul Razak","year":"2016","unstructured":"Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ et al (2016) First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol 34(34):4142\u20134150. https:\/\/doi.org\/10.1200\/JCO.2015.65.3949","journal-title":"J Clin Oncol"},{"issue":"9","key":"10169_CR131","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood-2016-11-752840","volume":"130","author":"KR Machlus","year":"2017","unstructured":"Machlus KR, Wu SK, Vijey P, Soussou TS, Liu ZJ, Shacham E et al (2017) Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood 130(9):1132\u20131143. https:\/\/doi.org\/10.1182\/blood-2016-11-752840","journal-title":"Blood"},{"key":"10169_CR132","doi-asserted-by":"publisher","unstructured":"Heong VYM, Koe P, Yong WP, Soo R, Chee CE, Wong A et al (2016) RAS\/AKT pathway mutations as predictive biomarkers in patients with colorectal cancer treated with the exportin 1 (XPO1) inhibitor selinexor (SEL) - inhibition of nuclear-cytoplasmic translocation of p27 as a mechanism of anti-tumour activity. Ann Oncol, 27. https:\/\/doi.org\/10.1093\/annonc\/mdw368.26.","DOI":"10.1093\/annonc\/mdw368.26"},{"issue":"7310","key":"10169_CR133","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nature09303","volume":"466","author":"S Ito","year":"2010","unstructured":"Ito S, D\u2019Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y (2010) Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466(7310):1129\u20131133. https:\/\/doi.org\/10.1038\/nature09303","journal-title":"Nature"},{"issue":"7","key":"10169_CR134","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1101\/gad.276568.115","volume":"30","author":"KD Rasmussen","year":"2016","unstructured":"Rasmussen KD, Helin K (2016) Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev 30(7):733\u2013750. https:\/\/doi.org\/10.1101\/gad.276568.115","journal-title":"Genes Dev"},{"issue":"1","key":"10169_CR135","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1186\/s12885-018-4579-z","volume":"18","author":"E Barazeghi","year":"2018","unstructured":"Barazeghi E, Prabhawa S, Norlen O, Hellman P, Stalberg P, Westin G (2018) Decrease of 5-hydroxymethylcytosine and TET1 with nuclear exclusion of TET2 in small intestinal neuroendocrine tumors. BMC Cancer 18(1):764. https:\/\/doi.org\/10.1186\/s12885-018-4579-z","journal-title":"BMC Cancer"},{"issue":"7","key":"10169_CR136","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.Mct-12-1171","volume":"12","author":"RAS Fragomeni","year":"2013","unstructured":"Fragomeni RAS, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao HS et al (2013) CRM1 and BRAF Inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Mol Cancer Ther 12(7):1171\u20131179. https:\/\/doi.org\/10.1158\/1535-7163.Mct-12-1171","journal-title":"Mol Cancer Ther"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-10169-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-10169-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-10169-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:38:40Z","timestamp":1766853520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-10169-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":136,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10169"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-10169-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"87"}}